Müller-Forell, WS; Schulze Frenking, G; Amraoui, Y et al.
Mucopolysaccharidoses (MPS) Clinical and neuroradiological aspects of the different typesClinical Neuroradiology. Bd. 17. H. 3. 2007 S. 141-158
Müller-Forell, WS; Schulze Frenking, G; Amraoui, Y et al.
Mucopolysaccharidoses (MPS) Clinical and Neuroradiological Aspects of the different types.Klin Neuroradiol. Bd. 17. 2007 S. 141-158
Karageorgos, L; Brooks, DA; Pollard, A et al.
Mutational analysis of 105 mucopolysaccharidosis type VI patientsHum Mutat. Bd. 28. 2007 S. 897-903
Hoffmann, B; Beck, M; Sunder-Plassmann, G et al.
Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.Clin J Pain. Bd. 23. H. 6. 2007 S. 535-42
Beck, M
New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapyHum Genet. Bd. 121. 2007 S. 1-22
Brenner, W; Voigt, R; Steinwender, C et al.
Nierentumoren: Bedeutung des Tumorsuppressors PTEN in NierentumorenUrologe. Bd. 46. H. 9. 2007 S. 1167
Pitz, S; Ogun, O; Bajbouj, M et al.
Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy: a 4-year experience.Arch Ophthalmol. Bd. 125. H. 10. 2007 S. 1353-6
Sodi, A; Ioannidis, AS; Mehta, A et al.
Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey.Br J Ophthalmol. Bd. 91. H. 2. 2007 S. 210-4
Kopp, MV; Stenglein, S; Kamin, W et al.
Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects.Pediatr Allergy Immunol. Bd. 18. H. 6. 2007 S. 523-7
Knuf, M; Schmitt, HJ
Osteomyelitis3. Aufl. Springer Verlag 2007 1672 S.